Report Overview

The women’s healthcare market's growth is mainly driven by factors such as the rising incidence of chronic illnesses among women, government initiatives to curb population, and growing requests for contraceptives to avoid unintentional pregnancies.

Global Women’s Healthcare Market- Industry Trends & Forecast Report 2027

The women’s healthcare market was worth USD 33,182.02 million in 2020 and is further expected to register a CAGR of 4.9% during the forecast period to attain a market value of 46,163.53 million by 2027. The global women’s healthcare market growth is mainly driven by factors such as the rising incidence of chronic illnesses among women, government initiatives to curb population, and growing demand for contraceptives to avoid unintentional pregnancies. Moreover, the growing focus on R&D by key players for the development of advanced products is also another major factor contributing to the growth of the global women’s healthcare market.

Global Women’s Healthcare Market Overview

Ailments and treatments relating to a woman's anatomy and reproductive organs are referred to as "women's health." A woman encounters several issues related to menstruation, pregnancy, menopause, and others throughout her life. Women's health also includes medical situations in which women face problems not directly linked to their biology but due to gender-differentiated admittance to medical cure. Women's health issues have gained increasing recognition in recent years worldwide. Effective policies and government initiatives have led to a reduction in women's ailments and have allowed them to live healthier lives. However, some significant gender-based health disparities prevail in many countries. Also, lack of awareness and lower-income levels in many developing countries remain obstacles making health progress for women very difficult.

Global Women’s Healthcare Market Forecast and Trends

Growth Drivers

The Rise in women-specific health disorders driving the growth of the global women’s healthcare market

According to the International Osteoporosis Foundation (IOF), the global incidence of osteoporosis among females is expected to reach 680 million in 2050. The Society of Obstetricians and Gynaecologists of Canada (SOGC) stated that up to 80% of women suffer from at least one symptom of menopause, such as mood swings, interrupted sleep, and irritability. The 2018 GLOBOCAN report by the International Agency for Research on Cancer (IARC) stated that female breast cancer diagnoses were prevalent in 2.1 million females in 2018, responsible for approximately 11.6% of the total global cancer burden. Thus, due to the rapid rise in the number of women-specific health disorders, the global women’s healthcare market is growing significantly in order to treat those disorders.

Changing lifestyle and lifestyle-associated disorders fueling the growth of the global women’s healthcare market

A fast-paced and hectic lifestyle has resulted in a variety of hazardous lifestyle choices, such as poor eating habits, sedentary lifestyle, and inconsistent sleeping patterns, among others. One of the most notable lifestyle disorders in women is PCOS. Additionally, an unhealthy diet has led to a major deficiency of iron in most women leading to anemia. Other lifestyle disorders include obesity, infertility, diabetes, general anxiety disorder, and others. According to an estimate, 68% of women suffer from lifestyle disorders, and 53% skip meals and opt for junk food due to work pressure deadlines. Additionally, 80% of urban Indian working women within the age range of 25-45 are overweight due to stress and a sedentary lifestyle. Thus, the prevalence of such a wide variety of disorders owing to lifestyle change has led to the growth of the demand for various drugs thereby augmenting the global women’s healthcare market.

Restraints

Lack of awareness regarding women’s healthcare and improper facilities

The biggest and most visible impediment to the global women's healthcare industry is a lack of awareness regarding women's healthcare, which has resulted in the majority of ailments going untreated. According to the WHO, 222 million women do not have access to contraceptive services in order to maintain reproductive health. Also, most developing nations lack adequate childbirth facilities, resulting in 300,000 women dying from complications during childbirth in 2013. Every year, about 13 million young females, mostly under the age of 20, give birth or suffer from pregnancy complications, which could also lead to unsafe abortion. Additionally, 4.7 million women in low- and middle-income countries die from non-communicable diseases before reaching the age of 70. Thus, a majority of women suffer from such diseases throughout their lives without getting proper treatment. Thus, owing to lack of awareness, due to various reasons, most disorders remain untreated, which is a massive restraint to the global women’s healthcare market.

Impact of COVID-19 on Global Women’s Healthcare Market

Previous experiences with the Ebola and Zika epidemics have shown that in such a crisis, existing gender disparities in healthcare are exacerbated. The Covid-19 pandemic has had a greater impact in numerous areas, both at work and at home, due to increased workload as a result of lockdown and quarantine restrictions. Women are also at a higher risk of anxiety, sadness, and post-traumatic stress disorder. These significant concerns have sparked a discussion on the importance of focusing on women's healthcare during the pandemic phase. It has created new potential for the growth of the women's healthcare sector.

During the pandemic, less than 20% of women in South Africa and Mozambique used family planning and other reproductive health services. COVID-19 has made it difficult for 60% of women in Azerbaijan and Turkey to get gynecological and obstetric care. The global crisis of decline in women's healthcare in the midst of the pandemic has prompted numerous governments to enter new markets and develop innovative ways to improve services to the female population. thereby creating market potential and demand for the women's healthcare sector.

Global Women’s Healthcare Market- By Drug Type

Based on drug type, the global women’s healthcare market is bifurcated into EVISTA, XGEVA, Prolia, Zometa, Reclast/Aclasta, Minastrin 24 Fe, FORTEO, Premarin, ACTONEL, Others. Prolia, EVISTA, XGEVA, Zometa, are considered to be the key drugs in the women’s healthcare industry, among which Prolia held the largest market share in 2020 and is further expected to grow at a strong CAGR during the forecast period (2021-2027). The growth in this segment can be attributed to the increasing number of cases of postmenopausal osteoporosis globally. Additionally, the growth can be attributed to the decreasing bone strength in women with time. Prolia aids in increasing bone mass and retaining bone strength in the body.

Global Women’s Healthcare Market- By Application

Based on application, the global women’s healthcare market has been segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, polycystic ovary syndrome. The postmenopausal osteoporosis segment accounted for the largest share in the global women’s healthcare market in 2020 and is projected to register a fast growth rate in the upcoming years. The menopause segment accounted for the least market share in 2020 and the growth for the segment can be attributed to the rise in cases of menopause as surgical removal of the ovaries, as well as medical therapies, such as radiation therapy and chemotherapy, can cause early or premature menopause.

Global Women’s Healthcare market- By Region

Based on the region, the global women’s healthcare market has been divided into North America, Europe, the Asia-Pacific, Latin America and the Middle East and Africa. North America accounted for the largest market share in 2020 and is likely to maintain its dominance over the forecast period. Europe held the second-largest market share owing to the ongoing research and development activities carried out in the healthcare sector across the region. The Asia Pacific is a rapidly growing market that is projected to expand at the highest CAGR among all regions during the forecast period. There are a significant number of female patients in the region constantly pursuing high-quality therapeutic care for chronic diseases. The region's healthcare sector is increasing rapidly owing to that spending. Additionally, due to the lack of specialist healthcare facilities in developing parts of the Middle East and Africa region, the region records sluggish growth in comparison to other regions.   

Competitive Landscape

Advances in digitalization, growing investments in R&D, and an increase in the number of women-related diseases and disorders have all aided market players to strengthen their product portfolios. The prominent market players operating in the women's healthcare market are Bayer AG, Allergan, Becton & Dickson, Elly Lilly, Merck & Co, Pfizer Inc., Amgen, Agile Therapeutics Inc., Ferring Pharmaceuticals Mylan N.V., and other prominent players. Among the main strategies adopted by these players for gaining a competitive advantage are investments in R&D, partnerships with other market participants, and mergers & acquisitions.

Recent Developments

• In May 2021, Merck (an American multinational pharmaceutical company) announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.  

• In February 2021, Ferring, Rebiotix and MyBiotics collaborated to develop live microbiome-based therapeutics in reproductive medicine and maternal health.  It aims to create standardized, stabilized live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy, and fertility issues.

Scope of Report

By Drugs         

• EVISTA
• XGEVA
• Prolia
• Zometa
• Reclast/Aclasta
• Minastrin 24 Fe
• FORTEO,
• Premarin
• ACTONEL
• Others

By Application

• Hormonal Infertility
• Postmenopausal Osteoporosis
• Endometriosis
• Contraceptives
• Menopause
• Polycystic Ovary Syndrome
• Others

By End-User

• Hospitals & Clinics
• Gynecology Centers
• Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa